HomeVBIV • NASDAQ
add
VBI Vaccines Inc
Previous close
$0.60
Day range
$0.59 - $0.62
Year range
$0.45 - $3.47
Market cap
17.39M USD
Avg Volume
763.39K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 853.00K | 191.13% |
Operating expense | 10.27M | -44.18% |
Net income | -13.00K | 99.94% |
Net profit margin | -1.52 | 99.98% |
Earnings per share | — | — |
EBITDA | -11.89M | 43.16% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 23.68M | -62.18% |
Total assets | 86.95M | -43.93% |
Total liabilities | 79.42M | -12.65% |
Total equity | 7.53M | — |
Shares outstanding | 28.43M | — |
Price to book | 2.32 | — |
Return on assets | -32.93% | — |
Return on capital | -46.42% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -13.00K | 99.94% |
Cash from operations | -12.06M | 36.70% |
Cash from investing | -170.00K | 88.29% |
Cash from financing | 272.00K | — |
Net change in cash | -11.77M | 43.75% |
Free cash flow | -12.98M | -0.72% |
About
Variation Biotechnologies Inc., also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Ontario, Canada, and a research and manufacturing site in Rehovot, Israel. Its Ottawa facility has approximately thirty researchers working with National Research Council of Canada to produce a COVID-19 vaccine—VBI-2902. In August VBI received CA$56 million from the Government of Canada to prepare its vaccine for clinical trials by the end of 2020. The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines. Wikipedia
Founded
1965
Website
Employees
131
